Download - Drug Study (Cp)
-
7/30/2019 Drug Study (Cp)
1/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G: Paracetamol,
Acetaminophen
B: Biogesic, Panadol,
Tylenol
C: Non-narcotic
analgesic, Antipyretic
300 mg IVTT then q 4 hrs
PRN for T= 38 degreescelsius
Inhibits the synthesis of
prostaglandin that servesas mediators of pain and
fever, primarily in the
CNS. Analgesia
Mild pain and fever. Hypersensitivity, renal
insufficiency, anemia.
GI: hepatic failure,
hepatotoxicity (overdose)
GU: renal failure
Hemat: neutropenia,
pancytopenia, leucopenia
Derm: rash, urticaria
Assess overall h
status and alcobefore administ
Assess amount,
frequency, and
of drugs taken
patients self-
medicating, esp
with OTC drugs
Pain: Assess typ
location, intens
prior to and 30-
min following
administration
Fever: Assess fe
note presence o
associated sign
(diaphoresis,
tachycardia, an
malaise).
Report nausea
vomiting, cyano
SOB, and abdom
pain as these ar
of toxicity.
-
7/30/2019 Drug Study (Cp)
2/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G:Piperacillin /
Tazobactam
B: Zosyn
C: Anti-infective
4.5 gm IVTT q 8 hrs ANST
(-)
Piperacillin
: Binds to bacterial cell
wall membrane, causing
cell death. Spectrum is
extended compared with
other penicillins
Tazobactam
: Inhibits beta-lactamase,
an enzyme that can
destroy penicillins
Treatment of moderate to
severe appendicitis,
uncomplicated and
complicated skin and skin
structure infections.
Hypersensitivity to
penicillins,cephalosphorins, or other
drugs. Safety in childrenamebic hepatic abscess
>intestinal amebiasis
>trichomoniasis
>retractory
trichomoniasis
>bacterial infection
caused by anaerobic
microorganisms
>to prevent postoperative infection
incontaminated
colorectal surgery
>pelvic inflammatory
disease
Breast-feeding,
hypersensitivity tometronidazole or its
components,
trichomoniasis during first
trimester of pregnancy.
CNS: Ataxia, dizziness,
encephalopathy, fever,headache, light-
headedness, peripheral
neuropathy, seizures
(highdoses)
EENT: Dry mouth,
lacrimation (topical
form),metallic taste,
pharyngitis
GI: Abdominal cramps or
pain, anorexia, diarrhea,
nausea, pancreatitis,vomiting
GU: Darkened urine,
vaginal candidiasis (oral,
parenteral, and topical
forms); burning or
irritation of sexual
partners, dysuria, urinary
frequency,
If pt has advers
reactions, suchseizures or peri
neuropathy, te
prescriber and
drug immediate
Monitor pt
severe liver
disease bec
slowed
metronida
metabolism
cause drug
accumulate
body and inthe risk of
adverse eff
If skin irrita
occurs, app
topical gel
frequently
discontinue
ordered.
Monitor CB
culture and
sensitivity t
therapy las
longer than
days or if s
course of
treatment
needed
Give IV dru
-
7/30/2019 Drug Study (Cp)
6/15
slow infusio
1 hr; dont
direct IN
injection.
-
7/30/2019 Drug Study (Cp)
7/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsib
G: Bisacodyl
B: Dulcolax
C: Gastrointestinal agent /
Laxative
2 suppository Expands
intestinal fluid
volume by
increasing
epithelial
permeability.
Induces
peristaltic
contractions by
direct
stimulation of
sensory nerve
endings in the
colonic wall.
Temporary relief of acute
constipation and for
evacuation of colon
before surgery,
proctoscopic,
sigmoidoscopic, and
radiologic examinations.
Also used tocleanse
colonbeforedeliveryand
torelieve constipationin
patients withspinal cord
damage.
Ileus, intestinal
obstruction, acute
surgical abdominal
conditions;
severedehydration.
Appendicitis & acute
inflammatory bowel
diseases.
Rarely, abdominal
discomfort & diarrhoea.
Evaluate
periodicall
patients nfor continu
of drug;
bisacodyl u
produces 1
soft forme
stools daily
Monitor pa
receiving
concomita
anticoagul
Indiscriminuse of laxa
results in
decreased
ption of vit
K.
Add high-fi
foods slow
regular die
avoid gas a
diarrhea.
Adequate f
intakeinclu
least 68
glasses/d.
-
7/30/2019 Drug Study (Cp)
8/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G: Methylprednisolone
B: Medrol
C: Corticosteroid (Anti-
inflammatory)
Glucocorticoid
Hormone
8 mg 1 tab Enters target cells and
binds to intracellularcorticosteroid receptors,
initiating many complex
reactions that are
responsible for its anti-
inflammatory and
immunosuppressive
effects.
Hypercalcemia
associated with cancer
Short-term
management of various
inflammatory and
allergic disorders, such
as rheumatoid arthritis,
collagen diseases (eg,
SLE), dermatologic
diseases and
autoimmune disorders.
Contraindicated with
infections, especially
tuberculosis, fungal
infections:lactation;
allergy to tartrazine
Use cautiously with
kidney or liver disease,
hypothyroidism,
ulcerative colitisr,
inflammatory bowel
disease, CHF,
hypertension,
osteoporosis, seizure
disorders, diabetes
mellitus, pregnancy.
CNS: Vertigo, headache,
paresthesias, insomnia,seizures,
CV:Hypot ension, shock,
hypertension and CHF
secondary to fluid
retention,
thrombophlebitis,
Electrolyte imbalance: Na+
and fluid retention,
hypokalemia,hypocalcemia
Endocrine: Amenorrhea,
irregular menses, growth
retardation, decreased
carbohydrate tolerance,
diabetes mellitus,
GI: Peptic or esophageal
ulcer, pancreatitis,
abdominal distention,
nausea, vomiting,
increased appetite, weight
gain
Musculoskeletal: Muscle
weakness, steroid, loss of
muscle mass, osteoporosis
Other:
Immunosuppression;
History: Infections;
or liver disease,
hypothyroidism,
ulcerative colitis,diverticulitis, active
latent peptic ulcer,
inflammatory bowe
disease, CHF,
hypertension,
thromboembolic
disorders, osteopor
seizure disorders,
diabetes mellitus;
pregnancy; lactatio
Physical: Weight, T,
reflexes and grip staffect and orientat
BP, peripheral perf
prominence of supe
veins, R and advent
sounds, serum
electrolytes, blood
glucose.
Give daily dose bef
AM to mimic norm
corticosteroid bloo
levels.
Increase dosage wh
patient is subject to
stress.
-
7/30/2019 Drug Study (Cp)
9/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G: Tramadol
B: Ultram
C: Analgesic
50 mg IV q 8 hrs PRN for
pain
Binds to mu-opioid
receptors.
Inhibits reuptake of
serotonin and
norepinephrine in the
CNS.
Decreased pain.
Moderate to moderately
severe pain.
Hypersensitivity;
pregnancy and lactation;renal impairment; history
of epilepsy because they
are at risk of seizure.
CNS: Seizure, dizziness,
headache
EENT: Visual
disturbances
CV: Vasodilation
GI: Constipation, nausea,
abdominal pain
GU: urinary frequency
Germ: Pruritus, swelling
Misc: physicaldependence, tolerance.
Assess type, location
intensity of pain befo2-3 hr (peak) after
administration.
Assess BP & RR befo
periodically during
administration. Resp
depression has not
occurred with
recommended doses
Assess bowel functio
routinely. Preventionconstipation should
instituted with incre
intake of fluids and b
and with laxatives to
minimize constipatin
effects.
Assess previous anal
history. Tramadol is
recommended for pa
dependent on opioid
who have previouslyreceived opioids for
than 1 wk; may caus
opioid withdrawal
symptoms.
-
7/30/2019 Drug Study (Cp)
10/15
Prolonged use may l
physical and psychol
dependence and tole
Tramadol is consider
provide more analge
than codeine 60 mg
than combined aspir
650mg/codeine 60 m
acute postoperative
Monitor patient for
seizures. May occur
recommended dose
Risk increased with h
doses and inpatients
antidepressants (SSR
tricyclics, or Mao
inhibitors), opioid
analgesics, or other d
that decrese the seiz
threshold.
Overdose may cause
respiratory depressio
seizures. Naloxone (
may reverse some, b
all, of the symptoms
overdose. Treatment
should be symptoma
supportive. Maintain
adequate respiratory
exchange.
Encourage patient to
and breathe deeply e
hr to prevent atelact
and pneumonia.
-
7/30/2019 Drug Study (Cp)
11/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G: NaHCO3 (Sodium
Bicarbonate)
B: Sodium Bicarbonate
C: Antacid
1 tab BID Acts as an alkalinizing
agent by releasingbicarbonate ions.
Neutralization of gastric
acid.
Treatment of metabolic
acidosis, promotion ofgastric, systemic and
urine alkalinization in the
case of intoxication with
weak organic acids.
Metabolic or
respiratory alkalosis;hypocalcemia; CHF; renal
insufficiency.
CNS: tetany
CV: edema
GI: gastric distention,
flatulence
Metabolic: hypokalemia,
hyponatremia
Obtain patie
history includrug history
hypersensit
Assess respiratory a
pulse rate, rhythm, d
lung sounds and not
physician.
Assess for carbon d
in GI tract, may lead
perforation if ulcer is
severe.
Test and monitor upH, urinary output, d
beginning treatment
If patient has edem
tendency, notify phy
If patient is vomitin
hold medication and
immediately inform
physician.
If the patient exhib
shortness of breath a
hyper apnea, immedinform the physician
Inform physician if
not obtained or if the
patient demonstrate
symptom suggest ble
-
7/30/2019 Drug Study (Cp)
12/15
such as black tarry st
coffee ground emesi
Caution patient to
immediately report t
physician if symptom
as nausea, vomiting
anorexia occurs.
Advise the patient t
notify the physician
indigestion occurs.
-
7/30/2019 Drug Study (Cp)
13/15
DRUG STUDY
BRAND NAME GENERIC
NAME CLASSIFICATION
Prescribed and
Recommended dosage,
frequency, route of
administration
Mechanism
Of
Action Indication Contraindication Adverse Reaction Nursing Responsi
G: Colchicine
B: Colcrys
C: Antigout agent
0.5 mg 1 tab Interferes with the
functions of WBCsinitiating and
perpetuating the
inflammatory response
to monosodium urate
crystals.
Decrease pain and
inflammation in acute
attacks of gout.
Acute attacks of gouty
arthritis.
Treatment of hepatic
cirrhosis and familial.
Serious GI, renal,
hepatic, or cardiac
disorders; blood
dyscrasias;
hypersensitivity to the
drug.
GI: Diarrhea, nausea and
vomiting, abdominal pain.
GU: Anuria, hematuria
Hemat: Aggranulocytosis,
anemia
Assess patie
toxicity (we
abdominal
discomfort,nausea, vom
difficulty
swallowing)
withhold dr
report symp
immediately
Assess invo
joints for pa
mobility, an
edema thro
therapy.
Monitor int
and output
Fluids shoul
encouraged
promote ur
output of at
2000 mL/da
Check CBC
periodically
patients
undergoing
term therap
Administer
great cautio
debilitated
patients andthose with e
manifestati
GI or cardia
disorders.
-
7/30/2019 Drug Study (Cp)
14/15
SUMMARY OF MEDICATION
DATE MEDICATIONS- dosage, frequency, route Remarks
November 22, 2012
November 23, 2012
November 25, 2012
November 26, 2012
Paracetamol 300 mg IVTT then q 4 hrs PRN for T=
38 degrees Celsius Piperacillin, Tazobactam 4.5 gm IVTT q 8 hrs ANST (-)
Omeprazole 40 mg IV OD
Metronidazole 500 mg IV q 8 hrs ANST (-)
Dulcolax 2 suppositories
Colchicine 0.5 mg 1 tab
Medrol 8 mg 1 tab
Tramadol 50 mg IV q 8 hrs PRN for pain
NaHCO3 (Sodium Bicarbonate) 1 tab BID
Given, tolerated and recorded
Given, tolerated and recordedGiven, tolerated and recorded
Given, tolerated and recorded
Given, tolerated and recorded
Given, taken, tolerated and recorde
Given, taken, tolerated and recorde
Given, tolerated and recorded
Given, taken, tolerated and recorde
-
7/30/2019 Drug Study (Cp)
15/15